Paul Hastings LLP advised Kyverna Therapeutics in connection with the company’s upsized initial public offering of 14,500,000 shares of common stock at an initial public offering price of $22.00 per share, for gross proceeds of approximately $319 million. In addition, Kyverna has granted the underwriters a 30-day option to purchase up to an additional 2,175,000 shares of common stock at the initial public offering price. Trading of common stock (Nasdaq: KYTX) is expected to begin February 8, 2024. Kyverna is a patient-centered clinical-stage biopharmaceutical company focuses on developing cell therapies for patients suffering from autoimmune diseases.

Partner and chair of the Corporate Practice in Palo Alto Jeff Hartlin and partner Samantha Eldredge led the Paul Hastings team, which included associates Youssef Aziz, Kelly Go, and Erik Oakley.

More details about the transaction can be found here.

About Paul Hastings

With widely recognized elite teams in finance, mergers & acquisitions, private equity, restructuring and special situations, litigation, employment, and real estate, Paul Hastings is a premier law firm providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers, and corporations.